SCHEMBL7124022

SCHEMBL7124022

CC(C)c1cccc(C[C]=O)c1C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 5/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRB2 P47870 4/20 0.38
LMNA P02545 2/20 0.38
FAAH O00519 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
GABRB1 P18505 1/20 0.38
PTGS1 P23219 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2C P28335 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
HTR2B P41595 1/20 0.38
GABRA2 P47869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249692 0.83 ACE2 (0.31)
SCHEMBL3247879 0.83 GABRA1 (0.34) GABRA1GABRG2GABRB3GABRB2LMNA
SCHEMBL7116908 0.82 GABRA1 (0.40) GABRA1GABRG2GABRB3GABRB2LMNA
SCHEMBL3088973 0.80 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRB2LMNA
SCHEMBL3249426 0.77 GABRA1 (0.35) GABRA1GABRG2GABRB3GABRB2LMNA
SCHEMBL7565776 0.76 GABRA1 (0.54) GABRA1GABRG2GABRB3GABRB2LMNA
SCHEMBL487534 0.75 GABRA1 (0.57) GABRA1GABRG2GABRB3GABRB2LMNA
SCHEMBL676937 0.75 GABRA1 (0.42) GABRA1GABRG2GABRB3GABRB2LMNA
SCHEMBL10349024 0.75 GABRA1 (0.42) GABRA1GABRG2GABRB3GABRB2LMNA
SCHEMBL29010590 0.74 GABRA1 (0.38) GABRA1GABRG2GABRB3GABRB2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 GABRA1 3569/4885GABRG2 4496/4885GABRB3 3763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.